DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV) today announced the launch of the Patient Centered Endpoints (PCE) solution, an innovative science and ...

See IQVIA’s new AI‑driven capabilities in the Clinical Trial Financial Suite (CTFS) in action—featuring live demos of CTFS Site Payments and Protocol Ingestion for CTFS GrantPlan. Learn how these ...

IQVIA Holdings has signed an agreement to acquire selected discovery service assets from Charles River Laboratories, aiming ...

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV) today announced that Chiesi Farmaceutici, the international research-focused healthcare Group (Chiesi Group) is ...

IQVIA Holdings Inc. (NYSE:IQV) is one of the most undervalued AI stocks to buy now. With significant analyst and hedge fund ...

New multiyear collaboration between Florence Healthcare and IQVIA to ensure research sites participating in IQVIA studies have access to best-in-class site enablement technology to streamline ...

IQVIA Holdings Inc. IQV yesterday unveiled a clinical trial technology platform, One Home for Sites. The platform streamlines the process of management of trials by acting as a single sign-on and a ...

IQVIA has announced a strategic, long-term partnership with Boehringer Ingelheim focused on strengthening data capabilities across therapeutic areas. As part of this agreement, Boehringer Ingelheim ...

Gross Leverage Ratio (Gross Debt/LTM Adjusted EBITDA) 4.9x Net Leverage Ratio (Net Debt/LTM Adjusted EBITDA) 4.5x ...

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and ...